Cronos Group (CRON) investor relations material

Executive summary

• Net revenue for Q1 2026 rose 40% year-over-year to $45.2 million, driven by strong cannabis flower sales in Israel and other international markets, and higher extract and flower sales in Canada.

• Achieved record net revenue and gross profit, with the ninth consecutive quarter of record net revenue in Israel and #1 market share in vapes and edibles in Canada.

• Maintained an industry-leading balance sheet with $822 million in cash and cash equivalents at quarter-end.

• Announced the pending acquisition of CanAdelaar, the largest operator in the Netherlands' legal adult-use cannabis market, with closing expected in summer 2026, recently extended to September 2026.

• Continued execution of a borderless products strategy, with significant momentum in international markets and product launches in Canada and Israel.

Financial highlights

• Gross profit increased 39% year-over-year to $19.2 million, with gross margin at 42%.

• Net income more than doubled to $15.7 million, up 103% from Q1 2025.

• Adjusted EBITDA improved 122% year-over-year to $5.1 million, marking the second-highest in company history.

• Operating expenses increased 18% year-over-year to $21.0 million, mainly due to higher G&A, sales, marketing, and R&D.

• Cash and cash equivalents stood at $822 million as of March 31, 2026.

Outlook and guidance

• Management expects continued sustainable net revenue and Adjusted EBITDA growth, leveraging expanded supply and international market momentum.

• The CanAdelaar acquisition is expected to close in summer 2026, expanding the European footprint, with closing extended to September 2026.

• Anticipates adverse gross margin impact in Q2 2026 from increased energy and shipping costs due to Middle East conflict.

• Ongoing focus on supply chain optimization, efficiency gains, and incremental yield improvements from the GrowCo expansion.